Syndax Pharmaceuticals (SNDX) is a commercial-stage biopharmaceutical company based in New York that sells two FDA-approved cancer therapies: Revuforj, a menin inhibitor for acute leukemias, and Niktimvo, an antibody for chronic graft-versus-host disease developed with Incyte. In trading on Thursday, the stock gained 4.79% to $8.97, compared with the prior session's close of $8.56, confirming an upward move of $0.41 per share. No verified news catalyst was found for the advance; the session instead looks consistent with an oversold rebound following the stock's slide to a 52-week low a day earlier.
No verified news or fundamental catalyst found in company disclosures, filings, or market reporting accounts for Thursday's gain. Syndax issued no press release, disclosed no new clinical data, and drew no analyst rating change or price target revision. The only scheduled corporate event was a fireside chat at the Jefferies London Healthcare Conference at 7:30 a.m. Eastern — a routine investor appearance that precedes the open rather than a disclosure event, though management commentary at such meetings can nudge sentiment in a thinly traded, heavily shorted name.
The more probable explanation is technical. The stock bottomed at $8.47 on Wednesday, a new 52-week low, and had fallen roughly 37% in the prior month. That left the shares deeply stretched below their 50-day and 200-day moving averages, near $14.60 and $19.50 respectively, with a 14-day relative strength index in the low 20s — a reading that often precedes short-lived mean-reversion rallies. With the stock down more than 50% year to date, sellers are less numerous and modest buying can move the tape meaningfully, particularly in a name with roughly 81 million freely tradable shares.
Thursday's bounce does little to alter a damaged narrative. On October 13, the shares fell about 16% after a Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint, prompting Syndax to abandon development in that indication. On November 2, the company reported third-quarter revenue of $83.3 million, up 82% year over year, with Revuforj net revenue of $60.7 million and Niktimvo net sales of $67.4 million. Revenue beat estimates, but a wider-than-expected adjusted loss of $0.55 per share, combined with the pipeline setback and the departure of the chief financial officer, triggered a 26.9% drop on November 4 and a further 10.3% decline the next day. Subsequent law-firm inquiries into the fibrosis program added an overhang. Any rally from here starts from a valuation that already assumes considerable execution risk.
Activity has been unusually heavy throughout the decline. Wednesday's session traded about 3.47 million shares against a three-month average near 2.5 million, and intraday amplitude exceeded 10%. Volatility of that scale tends to persist for several sessions rather than resolve in one, which is consistent with Thursday's rebound being part of a bottoming attempt rather than a clean reversal.
The advance looks idiosyncratic rather than sector-driven: it follows a company-specific selloff and a company-specific low, with no fresh industry catalyst behind it. Technically, the shares remain far below every major moving average, so the session represents a bounce inside a downtrend, not a trend change. The first meaningful resistance sits near the $9.40 level that capped Wednesday's rally attempt, with the prior earnings gap around $10.45 above that. Support is defined by Wednesday's $8.47 low.
The score runs from 0 to 100, where 0 means no meaningful news and a move in line with the stock's normal behavior, and 100 means transformative news paired with a rare, extreme price move. Syndax scores 19 out of 100.
Verified news was minimal: no release, filing, or analyst action accompanied the gain, and the sole scheduled event — an investor conference chat — carries little weight for a company of this size. The price move was also ordinary by the stock's own standards, roughly 1.6 times a typical daily swing of about 2.9%, and exceeded or matched eight times in the past 60 sessions. Weak news plus a routine move produces a low score.
Attention turns to December's American Society of Hematology annual meeting, where Syndax plans to present new Revuforj data across multiple trials and real-world studies, including front-line combination results. The company also expects to publish data in relapsed or refractory NUP98-rearranged acute leukemia during the fourth quarter, a publication that could support guideline inclusion. Beyond that, Niktimvo combination data in chronic graft-versus-host disease are expected in the first quarter of 2027, alongside the start of the MenTain maintenance trial.
Financially, Syndax ended the third quarter with $551 million in cash and guided 2026 research, development, selling, general and administrative expense to roughly $400 million, excluding stock compensation. Investors will scrutinize the pace of Revuforj growth as transplant pauses weigh on near-term revenue, competitive menin inhibitor launches, and the credibility of management's path to profitability. The next quarterly report is expected in late February 2027. Risks include further pipeline disappointments, reimbursement pressure, and continued legal scrutiny of the fibrosis program.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and traded symbols, allowing investors to compare approaches side by side. Amid swings like those in SNDX, reviewing how automated strategies are positioned can add a useful layer of perspective to your research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for SNDX entered a downward trend on November 17, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 208 similar instances where the Aroon Indicator formed such a pattern. In 169 of the 208 cases the stock moved lower. This puts the odds of a downward move at 81%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 72 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 31 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 220 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. SNDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (56.421) is normal, around the industry mean (3.592). P/E Ratio (-3.801) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals for novel cancer therapies
Industry Biotechnology